Fosun Pharma subsidiary licenses Alzheimer's drug for China

Fosun Pharma Industrial has entered a licensing agreement with Neucore for AR1001, targeting Alzheimer's and other neurological diseases in mainland China and Hong Kong.

The deal includes potential payments of up to 150 million yuan, comprising a 40 million yuan upfront payment and regulatory milestone payments of up to 110 million yuan, plus tiered sales-based royalties.